Compare Recursion Pharmaceuticals Inc (RXRX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tyson Foods, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Tyson Foods, Inc. trades at $57.25 (market cap $20.42B). The key difference: Tyson Foods, Inc. is far larger — about 13.3× Recursion Pharmaceuticals Inc's market cap, and Tyson Foods, Inc. pays a 3.52% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TSN | |
|---|---|---|
Market Cap | $1.53B | $20.42B |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $68.75 |
52-Week Low | $2.84 | $50.72 |
Enterprise Value | $946.50M | $28.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Tyson Foods (TSN) trades at $57.05, down 1.25% with neutral technical indicators. The company shows stable revenue near $54B but thin margins, with a 0.81% net income margin and elevated P/E of 45.67. Recent earnings beat expectations in Q1 2026, while analyst consensus is mixed with a $68.80 price target. Dividend payments continue at $0.51 quarterly.
TSN offers modest growth potential with analyst upside but faces margin pressure and competitive challenges. The stock's valuation appears stretched relative to earnings, while consistent dividends provide income support. Key risks include commodity cost volatility and execution in the competitive protein market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
